We know that, Fycompa (see structure, perampanel) is a selective, non-competitive AMPA receptor antagonist discovered by the research teams at Eisai laboratories. The development of an AMPA antagonist compound with a favourable pharmacokinetic and safety profile arose after the AMPA receptor was identified as a promising target for drug development. The AMPA receptor is widely present in almost all excitatory neurons. It is believed to play a role in a large number of central nervous system diseases with similar neuropathology.
1 comment:
Fycompa is now available, and approved by FDA for those with partial-onset seizures. However, according to http://www.rxwiki.com/fycompa it's not for everyone. It has not been approved for those under 12, and can have psychological side effects.
Post a Comment